The approval was based on data from the randomized, double-blind, parallel-arm phase 3 AWARD-11 trial. The Food and Drug Administration (FDA) has approved 2 additional dosage strengths of Trulicity ® ...
hba1c hemoglobin diabetes test At Week 24, both dulaglutide 0.75mg and 1.5mg added to ongoing SGLT-2 inhibitor therapy showed statistically superior glycemic control (-1.21% and -1.34%, respectively) ...
Once-weekly treatment for adults with type 2 diabetes comes in a pen with a no-see, no-handle needle INDIANAPOLIS, Nov. 10, 2014 /PRNewswire/ -- The newest GLP-1 receptor agonist treatment option to ...
Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise The single-dose pen does not require mixing nor ...
INDIANAPOLIS, June 9, 2019 /PRNewswire/ -- Detailed results from REWIND, the Trulicity ® (dulaglutide) cardiovascular outcome trial, showed a significant 12 percent reduction in major cardiovascular ...
AWARD-11 showed 3.0 mg and 4.5 mg doses led to additional blood sugar control; as a secondary endpoint, both doses also led to weight loss INDIANAPOLIS, Sept. 3, 2020 /PRNewswire/ -- The U.S. Food and ...
The new indication reflects the differentiated patient population of REWIND, the Trulicity cardiovascular outcomes trial. While all participants had CV risk factors, the study consisted primarily of ...
(MENAFN- PR Newswire) INDIANAPOLIS, June 13, 2020 /PRNewswire/ -- New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly ...
U.S. Trulicity Market to Reach USD 4.87 Billion by 2035 Driven by Rising Diabetes PrevalenceAustin, May 04, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Trulicity Market size was valued at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results